Johnson & Johnson’s venture capital arm, JJDC, has led a strategic investment in Distalmotion, following the company’s $150 million Series G financing in 2025. The infusion of capital will support the rollout of the DEXTER® Robotic Surgery System into ambulatory surgery centers (ASCs), a segment growing at an annual rate of more than 10% and accounting for over 2.5 million outpatient procedures per year in the US. DEXTER, purpose-built for outpatient settings, has secured US clearance for adult inguinal hernia repair, cholecystectomy and benign hysterectomy and has treated over 3,000 patients to date. Investors expect adoption to accelerate as ASCs pursue cost savings and enhanced surgeon recruitment, with payor policies increasingly favoring outpatient robotics for soft-tissue procedures.

Johnson & Johnson reported longer-term data from the OrigAMI-1 trial of amivantamab-vmjw (RYBREVANT®) plus FOLFOX or FOLFIRI chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer. At a median follow-up of 16 months, the overall response rate across 43 patients was 51% (95% CI, 36–67), with a median duration of response of 9.3 months (95% CI, 5.8–14.7) and median progression-free survival of 9.2 months (95% CI, 5.4–12.9). In the first-line subgroup (n=11), the confirmed response rate reached 73% and median duration of response was not yet reached. Notably, 57% of patients with liver metastases responded, and over one-third of second-line patients remained on therapy beyond one year. Only 9% discontinued due to treatment-related adverse events. These results underpin ongoing Phase 3 OrigAMI-2 and OrigAMI-3 studies and reinforce amivantamab’s dual-targeting potential in colorectal oncology.